Madrigal Pharmaceuticals, Inc. MDGL Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $958.4M+432% | $180.13M— | $0— | $0— | ||
| —— | $173.9M— | $0— | $0— | ||
| $388.53M+64.1% | $236.72M-13.1% | $272.35M+11.0% | $245.44M+19.6% | ||
| $813.83M+87.1% | $435.06M+302% | $108.15M+125% | $48.13M— | ||
| $1.26B+85.6% | $678.01M+78.2% | $380.5M+29.6% | $293.57M+21.1% | ||
| $56.15M-91.7% | $678.01M+78.2% | $380.5M+29.6% | $293.57M— | ||
| -$300.1M+39.7% | -$497.87M-30.8% | -$380.5M-29.6% | -$293.57M-21.1% | ||
| -31.3%+245pp | -276.4%— | —— | —— | ||
| $22.31M+52.1% | $14.67M+15.4% | $12.71M+221% | $3.96M— | ||
| -$463K— | $0— | $0— | $0-100% | ||
| -$288.28M+38.1% | -$465.89M-24.7% | -$373.63M-26.5% | -$295.35M-22.1% | ||
| -30.1%+229pp | -258.6%— | —— | —— | ||
| -$10.15— | —— | -$19.94-15.7% | -$17.23-17.9% | ||
| -$298.59M+39.9% | -$496.78M-30.7% | -$379.97M-29.6% | -$293.1M-21.1% | ||
| -31.2%+245pp | -275.8%— | —— | —— | ||
| -$300.1M+39.7% | -$497.87M-30.8% | -$380.5M-29.6% | -$293.57M-21.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s revenue?
- Madrigal Pharmaceuticals, Inc. (MDGL) generated $1.1B in revenue over the trailing twelve months, up 256.8% year over year.
- Is Madrigal Pharmaceuticals, Inc. profitable?
- Madrigal Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $309.4M over the trailing twelve months, a -27.3% net margin.
- What are Madrigal Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 96.5% and operating margin is -27.7%, with a -27.3% net margin.
- What is Madrigal Pharmaceuticals, Inc.'s earnings per share?
- Madrigal Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-10.79.
- Where does Madrigal Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Madrigal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
